Denali Therapeutics Inc. said on 16 February that SAR443820/DNL788, an oral brain-penetrant RIPK1 inhibitor co-developed with Sanofi, failed in the Phase II HIMALAYA clinical trial testing the drug in amyotrophic lateral sclerosis (ALS). The companies have moved three RIPK1 inhibitors into the clinic since entering into a collaboration in 2018 for which Sanofi paid Denali $125m up front, but they have yet to see success beyond Phase I for any of the drug candidates.
Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks
Phase II Trial In Multiple Sclerosis Ongoing
The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.